| IJD SYMPOSIUM |
|
| Year : 2018 | Volume
: 63
| Issue : 2 | Page : 125-130 |
|
|
Controversies in the management of cutaneous adverse drug reactions
Yashpal Manchanda1, Sudip Das2, Aarti Sarda3, Projna Biswas2
1 Department of Dermatology, Al Farwaniya, Abu Dhabi, United Arab Emirates
2 Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India
3 Department of Dermatology, Wizderm Skin and Hair Specialty Clinic, Wizderm Skin and Hair Specialty Clinic, Kolkata, West Bengal, India
Correspondence Address:
Dr. Yashpal Manchanda
Department of Dermatology, Al Farwaniya, Abu Dhabi
United Arab Emirates
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijd.IJD_585_17
|
|
|
Some cutaneous adverse drug reactions (CADRs) are severe life-threatening conditions due to multisystem involvements with a high morbidity and mortality rates ranging from 25 - 70% and require immediate medical care. But there are huge controversies regarding the management because large clinical trials are lacking. Most frequent discussion and division occur regarding the use of systemic corticosteroid as early intervention with corticosteroids controls inflammation. Corticosteroids are potent agents that target several intracellular processes to modify almost all components of inflammatory and immune responses but their impact on the long term disease course is not known. Controlled relapses of rash and hepatitis may occur as corticosteroids are tapered. A chronic HHV6 activation promoted by systemic steroids could explain these relapses. Second important issue is the use of antitubercular drugs (ATD) in case of CADR due to multidrug therapy of ATD. As both the tuberculosis and CADR are life threatening conditions and we can not spare treatment of tuberculosis for CADR, we should come to a conclusion which is not yet decided. In the same way the use of antileprotic MDT in CADR due to MDT raises a similar controversy. So, here we focus on those controversies and discuss the issues.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
